These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6497565)

  • 21. Schizophrenia: diagnostic criteria and outcome.
    Bland RC; Orn H
    Br J Psychiatry; 1979 Jan; 134():34-8. PubMed ID: 760921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of response to clozapine.
    Lieberman JA; Kane JM; Safferman AZ; Pollack S; Howard A; Szymanski S; Masiar SJ; Kronig MH; Cooper T; Novacenko H
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():126-8. PubMed ID: 7961556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
    Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
    Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced growth hormone and prolactin responses in schizophrenia research.
    Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine.
    Zemlan FP; Hirschowitz J; Sautter F; Garver DL
    Psychiatry Res; 1986 Jul; 18(3):239-55. PubMed ID: 2875478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Comparative study between schizophrenic and non-schizophrenic psychotic disorders.
    Peralta V; Cuesta MJ
    Br J Psychiatry; 1999 Mar; 174():243-8. PubMed ID: 10448450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schizophrenia: Schneider's first-rank symptoms and outcome.
    Bland RC; Orn H
    Br J Psychiatry; 1980 Jul; 137():63-8. PubMed ID: 7459541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schneider's first rank symptoms and continuous performance disturbance as indices of dysconnectivity of left- and right-hemispheric components of language in schizophrenia.
    Ceccherini-Nelli A; Turpin-Crowther K; Crow TJ
    Schizophr Res; 2007 Feb; 90(1-3):203-13. PubMed ID: 17113266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of apomorphine hydrochloride administration on serum concentrations of prolactin and growth hormone in cattle.
    Gorewit RC
    Experientia; 1981 Feb; 37(2):204-6. PubMed ID: 7238762
    [No Abstract]   [Full Text] [Related]  

  • 30. First-rank symptoms in the postacute schizophrenic: a follow-up study.
    Silverstein ML; Harrow M
    Am J Psychiatry; 1978 Dec; 135(12):1481-6. PubMed ID: 717561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kurt Schneider's concepts of psychopathy and schizophrenia: a review of the English literature.
    Crowhurst B; Coles EM
    Can J Psychiatry; 1989 Apr; 34(3):238-43. PubMed ID: 2655862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone responses to apomorphine HCl in schizophrenic patients on drug holidays and at relapse.
    Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Dermer SW; MacCrimmon DJ; Mitton J
    Br J Psychiatry; 1983 May; 142():482-8. PubMed ID: 6135481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Schneider's first rank symptoms--prevalence, diagnostic use and prognostic implications.
    Radhakrishnan J; Mathew K; Richard J; Verghese A
    Br J Psychiatry; 1983 Jun; 142():557-9. PubMed ID: 6882976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine findings in the schizophrenias.
    Garver DL
    Endocrinol Metab Clin North Am; 1988 Mar; 17(1):103-9. PubMed ID: 2897906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormones, dopamine receptors and schizophrenia.
    Meltzer HY; Busch D; Fang VS
    Psychoneuroendocrinology; 1981; 6(1):17-36. PubMed ID: 7244055
    [No Abstract]   [Full Text] [Related]  

  • 36. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
    Rotrosen J; Angrist B; Gershon S; Paquin J; Branchey L; Oleshansky M; Halpern F; Sachar EJ
    Br J Psychiatry; 1979 Nov; 135():444-56. PubMed ID: 540209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems.
    Keks NA; Copolov DL; Kulkarni J; Mackie B; Singh BS; McGorry P; Rubin RT; Hassett A; McLaughlin M; van Riel R
    Biol Psychiatry; 1990 Jun; 27(11):1203-15. PubMed ID: 2354227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects.
    Kahn RS; Davidson M; Hirschowitz J; Stern RG; Davis BM; Gabriel S; Moore C; Davis KL
    Psychiatry Res; 1992 Feb; 41(2):155-61. PubMed ID: 1574542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings.
    Szymanski S; Lieberman J; Pollack S; Safferman A; Munne R; Umbricht D; Kane J; Kronig M; Chakos M; Cooper T
    Biol Psychiatry; 1995 Jan; 37(1):52-5. PubMed ID: 7893860
    [No Abstract]   [Full Text] [Related]  

  • 40. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.